


(Rac)-WAY-161503

| | | |
|--------------------|--|----------------|
| Cat. No.: | HY-103138A | |
| CAS No.: | 75704-24-4 | |
| Molecular Formula: | C ₁₁ H ₁₁ Cl ₂ N ₃ O | |
| Molecular Weight: | 272.13 | |
| Target: | 5-HT Receptor | |
| Pathway: | GPCR/G Protein; Neuronal Signaling | |
| Storage: | Powder | -20°C 3 years |
| | In solvent | -80°C 6 months |
| | | -20°C 1 month |



SOLVENT & SOLUBILITY

| In Vitro | DMSO : 100 mg/mL (367.47 mM; Need ultrasonic) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|--|---|-----------|-----------|------------|------------|-------|---------------|--|--|--|--|------|--|-----------|------------|------------|------|--|-----------|-----------|-----------|-------|--|-----------|-----------|-----------|--|--|--|
| | Preparing Stock Solutions | <table border="1"> <thead> <tr> <th>Solvent</th> <th>Mass</th> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>Concentration</td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>1 mM</td> <td></td> <td>3.6747 mL</td> <td>18.3736 mL</td> <td>36.7471 mL</td> </tr> <tr> <td>5 mM</td> <td></td> <td>0.7349 mL</td> <td>3.6747 mL</td> <td>7.3494 mL</td> </tr> <tr> <td>10 mM</td> <td></td> <td>0.3675 mL</td> <td>1.8374 mL</td> <td>3.6747 mL</td> </tr> </tbody> </table> | Solvent | Mass | 1 mg | 5 mg | 10 mg | Concentration | | | | | 1 mM | | 3.6747 mL | 18.3736 mL | 36.7471 mL | 5 mM | | 0.7349 mL | 3.6747 mL | 7.3494 mL | 10 mM | | 0.3675 mL | 1.8374 mL | 3.6747 mL | | | |
| | | Solvent | Mass | 1 mg | 5 mg | 10 mg | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Concentration | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | 1 mM | | 3.6747 mL | 18.3736 mL | 36.7471 mL | | | | | | | | | | | | | | | | | | | | | | | | |
| 5 mM | | 0.7349 mL | 3.6747 mL | 7.3494 mL | | | | | | | | | | | | | | | | | | | | | | | | | | |
| 10 mM | | 0.3675 mL | 1.8374 mL | 3.6747 mL | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (9.19 mM); Clear solution | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (9.19 mM); Clear solution | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (9.19 mM); Clear solution | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

BIOLOGICAL ACTIVITY

| | | |
|---------------------------|--|--|
| Description | (Rac)-WAY-161503 is a potent, selective, highly affinity 5-HT _{2C} receptor agonist with a K _i of 4 nM and an EC ₅₀ of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT _{2C} than 5-HT _{2A} and 5-HT _{2B} receptors. (Rac)-WAY-161503 has anti-obesity and antidepressant effects ^{[1][2]} . | |
| IC ₅₀ & Target | 5-HT _{2C} Receptor 4 nM (K _i) | 5-HT _{2C} Receptor 12 nM (EC ₅₀) |
| In Vivo | (Rac)-WAY-161503 (3-30 mg/kg; intraperitoneal injection; male C57BL/6J mice) dose-dependently decreases locomotor | |

activity, an effect that is blocked by the 5-HT_{2C/2B} antagonist SER-082^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| | |
|-----------------|--|
| Animal Model: | Male C57BL/6J mice with hallucinogen 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) ^[1] |
| Dosage: | 3 mg/kg, 10 mg/kg, 30 mg/kg |
| Administration: | Intraperitoneal injection (i.p.) |
| Result: | Dose-dependently decreased locomotor activity, an effect that was blocked by the 5-HT _{2C/2B} antagonist SER-082. |

REFERENCES

[1]. Halberstadt AL, et al. 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. *Neuropsychopharmacology*. 2009 Jul;34(8):1958-67.

[2]. Welmaker GS, et al. Synthesis and 5-hydroxytryptamine (5-HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[1,2-a]quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxalines. *Bioorg Med Chem Lett*. 2000 Sep 4;10(17):1991-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA